Literature DB >> 24798523

Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study.

Frederick A Masoudi, Xiaojuan Mi, Lesley H Curtis, Pamela N Peterson, Jeptha P Curtis, Gregg C Fonarow, Stephen C Hammill, Paul A Heidenreich, Sana M Al-Khatib, Jonathan P Piccini, Laura G Qualls, Adrian F Hernandez.   

Abstract

BACKGROUND: Trials comparing implantable cardioverter-defibrillator (ICD) therapy with cardiac resynchronization therapy with a defibrillator (CRT-D) are limited to selected patients treated at centers with extensive experience.
OBJECTIVE: To compare outcomes after CRT-D versus ICD therapy in contemporary practice.
DESIGN: Retrospective cohort study using the National Cardiovascular Data Registry's ICD Registry linked with Medicare claims.
SETTING: 780 U.S. hospitals implanting both CRT-D and ICD devices. PATIENTS: 7090 propensity-matched patients older than 65 years with reduced left ventricular ejection fraction (<0.35) and prolonged QRS duration on electrocardiography (≥120 ms) having CRT-D or ICD implantation between 1 April 2006 and 31 December 2009. MEASUREMENTS: Risks for death, readmission, and device-related complications over 3 years.
RESULTS: Compared with ICD therapy, CRT-D was associated with lower risks for mortality (cumulative incidence, 25.7% vs. 29.8%; adjusted hazard ratio [HR], 0.82 [99% CI, 0.73 to 0.93]), all-cause readmission (cumulative incidence, 68.6% vs. 72.8%; adjusted HR, 0.86 [CI, 0.81 to 0.93]), cardiovascular readmission (cumulative incidence, 45.0% vs. 52.4%; adjusted HR, 0.80 [CI, 0.73 to 0.88]), and heart failure readmission (cumulative incidence, 24.3% vs. 29.4%; adjusted HR, 0.78 [CI, 0.69 to 0.88]). It was also associated with greater risks for device-related infection (cumulative incidence, 1.9% vs. 1.0%; adjusted HR, 1.90 [CI, 1.07 to 3.37]). The lower risks for heart failure readmission associated with CRT-D compared with ICD therapy were most pronounced among patients with left bundle branch block or a QRS duration at least 150 ms and in women. LIMITATIONS: Patients were not randomly assigned to treatment groups, and few patients could be propensity-matched. The findings may not extend to younger patients or those outside of fee-for-service Medicare.
CONCLUSION: In older patients with reduced left ventricular ejection fraction and prolonged QRS duration, CRT-D was associated with lower risks for death and readmission than ICD therapy alone. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Entities:  

Mesh:

Year:  2014        PMID: 24798523     DOI: 10.7326/M13-1879

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

Review 1.  Do We Need an Implantable Cardioverter-defibrillator for Primary Prevention in Cardiac Resynchronisation Therapy Patients?

Authors:  Demosthenes G Katritsis; Angelo Auricchio
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

Review 2.  The Prevention of Hospital Readmissions in Heart Failure.

Authors:  Boback Ziaeian; Gregg C Fonarow
Journal:  Prog Cardiovasc Dis       Date:  2015-10-21       Impact factor: 8.194

3.  Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.

Authors:  Lucas N Marzec; Pamela N Peterson; Haikun Bao; Jeptha P Curtis; Frederick A Masoudi; Paul D Varosy; Steven M Bradley
Journal:  JAMA Cardiol       Date:  2017-05-01       Impact factor: 14.676

4.  Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.

Authors:  Prateeti Khazanie; Melissa A Greiner; Sana M Al-Khatib; Jonathan P Piccini; Mintu P Turakhia; Paul D Varosy; Frederick A Masoudi; Lesley H Curtis; Adrian F Hernandez
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

5.  Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.

Authors:  Ryan T Borne; Frederick A Masoudi; Jeptha P Curtis; Matthew M Zipse; Amneet Sandhu; Jonathan C Hsu; Pamela N Peterson
Journal:  JAMA Netw Open       Date:  2021-01-04

6.  Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement.

Authors:  Samaneh Salimian; Marc W Deyell; Jason G Andrade; Santabhanu Chakrabarti; Matthew T Bennett; Andrew D Krahn; Nathaniel M Hawkins
Journal:  Heart Rhythm O2       Date:  2021-12-17

7.  Complications after Surgical Procedures in Patients with Cardiac Implantable Electronic Devices: Results of a Prospective Registry.

Authors:  Katia Regina da Silva; Caio Marcos de Moraes Albertini; Elizabeth Sartori Crevelari; Eduardo Infante Januzzi de Carvalho; Alfredo Inácio Fiorelli; Martino Martinelli; Roberto Costa
Journal:  Arq Bras Cardiol       Date:  2016-08-29       Impact factor: 2.000

Review 8.  Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults.

Authors:  Paul L Hess; Daniel D Matlock; Sana M Al-Khatib
Journal:  Clin Cardiol       Date:  2019-12-23       Impact factor: 2.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.